These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

940 related items for PubMed ID: 25858641

  • 1. Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis.
    Huang J, Beyer C, Palumbo-Zerr K, Zhang Y, Ramming A, Distler A, Gelse K, Distler O, Schett G, Wollin L, Distler JH.
    Ann Rheum Dis; 2016 May; 75(5):883-90. PubMed ID: 25858641
    [Abstract] [Full Text] [Related]

  • 2. Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis.
    Huang J, Maier C, Zhang Y, Soare A, Dees C, Beyer C, Harre U, Chen CW, Distler O, Schett G, Wollin L, Distler JHW.
    Ann Rheum Dis; 2017 Nov; 76(11):1941-1948. PubMed ID: 28814429
    [Abstract] [Full Text] [Related]

  • 3. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.
    Distler JH, Jüngel A, Huber LC, Schulze-Horsel U, Zwerina J, Gay RE, Michel BA, Hauser T, Schett G, Gay S, Distler O.
    Arthritis Rheum; 2007 Jan; 56(1):311-22. PubMed ID: 17195235
    [Abstract] [Full Text] [Related]

  • 4. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis.
    Wollin L, Maillet I, Quesniaux V, Holweg A, Ryffel B.
    J Pharmacol Exp Ther; 2014 May; 349(2):209-20. PubMed ID: 24556663
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages.
    Maier C, Ramming A, Bergmann C, Weinkam R, Kittan N, Schett G, Distler JHW, Beyer C.
    Ann Rheum Dis; 2017 Jun; 76(6):1133-1141. PubMed ID: 28209630
    [Abstract] [Full Text] [Related]

  • 6. Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis.
    Yoshizaki A, Yanaba K, Yoshizaki A, Iwata Y, Komura K, Ogawa F, Takenaka M, Shimizu K, Asano Y, Hasegawa M, Fujimoto M, Sato S.
    Arthritis Rheum; 2010 Aug; 62(8):2476-87. PubMed ID: 20506342
    [Abstract] [Full Text] [Related]

  • 7. Dipeptidylpeptidase 4 as a Marker of Activated Fibroblasts and a Potential Target for the Treatment of Fibrosis in Systemic Sclerosis.
    Soare A, Györfi HA, Matei AE, Dees C, Rauber S, Wohlfahrt T, Chen CW, Ludolph I, Horch RE, Bäuerle T, von Hörsten S, Mihai C, Distler O, Ramming A, Schett G, Distler JHW.
    Arthritis Rheumatol; 2020 Jan; 72(1):137-149. PubMed ID: 31350829
    [Abstract] [Full Text] [Related]

  • 8. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis.
    Akhmetshina A, Venalis P, Dees C, Busch N, Zwerina J, Schett G, Distler O, Distler JH.
    Arthritis Rheum; 2009 Jan; 60(1):219-24. PubMed ID: 19116940
    [Abstract] [Full Text] [Related]

  • 9. Heat shock protein 90 (Hsp90) inhibition targets canonical TGF-β signalling to prevent fibrosis.
    Tomcik M, Zerr P, Pitkowski J, Palumbo-Zerr K, Avouac J, Distler O, Becvar R, Senolt L, Schett G, Distler JH.
    Ann Rheum Dis; 2014 Jun; 73(6):1215-22. PubMed ID: 23661493
    [Abstract] [Full Text] [Related]

  • 10. Jun N-terminal kinase as a potential molecular target for prevention and treatment of dermal fibrosis.
    Reich N, Tomcik M, Zerr P, Lang V, Dees C, Avouac J, Palumbo K, Horn A, Akhmetshina A, Beyer C, Xie W, Bennett BL, Distler O, Schett G, Distler JH.
    Ann Rheum Dis; 2012 May; 71(5):737-45. PubMed ID: 22258492
    [Abstract] [Full Text] [Related]

  • 11. Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis.
    Beyer C, Reich N, Schindler SC, Akhmetshina A, Dees C, Tomcik M, Hirth-Dietrich C, von Degenfeld G, Sandner P, Distler O, Schett G, Distler JH.
    Ann Rheum Dis; 2012 Jun; 71(6):1019-26. PubMed ID: 22294631
    [Abstract] [Full Text] [Related]

  • 12. A novel inhibitor of Smad-dependent transcriptional activation suppresses tissue fibrosis in mouse models of systemic sclerosis.
    Hasegawa M, Matsushita Y, Horikawa M, Higashi K, Tomigahara Y, Kaneko H, Shirasaki F, Fujimoto M, Takehara K, Sato S.
    Arthritis Rheum; 2009 Nov; 60(11):3465-75. PubMed ID: 19877032
    [Abstract] [Full Text] [Related]

  • 13. Recombinant Adenosine Deaminase Ameliorates Inflammation, Vascular Disease, and Fibrosis in Preclinical Models of Systemic Sclerosis.
    Zhang Y, Zhu H, Layritz F, Luo H, Wohlfahrt T, Chen CW, Soare A, Bergmann C, Ramming A, Groeber F, Reuter C, Fornasini G, Soukhareva N, Schreiber B, Ramamurthy S, Amann K, Schett G, Distler JHW.
    Arthritis Rheumatol; 2020 Aug; 72(8):1385-1395. PubMed ID: 32182396
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Antifibrotic efficacy of nintedanib in a cellular model of systemic sclerosis-associated interstitial lung disease.
    Atanelishvili I, Akter T, Noguchi A, Vuyiv O, Wollin L, Silver RM, Bogatkevich GS.
    Clin Exp Rheumatol; 2019 Aug; 37 Suppl 119(4):115-124. PubMed ID: 31573469
    [Abstract] [Full Text] [Related]

  • 16. 2-Methoxyestradiol inhibits bleomycin-induced systemic sclerosis through suppression of fibroblast activation.
    Zhu L, Song Y, Li M.
    J Dermatol Sci; 2015 Jan; 77(1):63-70. PubMed ID: 25465161
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Src kinases in systemic sclerosis: central roles in fibroblast activation and in skin fibrosis.
    Skhirtladze C, Distler O, Dees C, Akhmetshina A, Busch N, Venalis P, Zwerina J, Spriewald B, Pileckyte M, Schett G, Distler JH.
    Arthritis Rheum; 2008 May; 58(5):1475-84. PubMed ID: 18438865
    [Abstract] [Full Text] [Related]

  • 19. Vitamin D receptor regulates TGF-β signalling in systemic sclerosis.
    Zerr P, Vollath S, Palumbo-Zerr K, Tomcik M, Huang J, Distler A, Beyer C, Dees C, Gela K, Distler O, Schett G, Distler JH.
    Ann Rheum Dis; 2015 Mar; 74(3):e20. PubMed ID: 24448349
    [Abstract] [Full Text] [Related]

  • 20. Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies.
    Dees C, Beyer C, Distler A, Soare A, Zhang Y, Palumbo-Zerr K, Distler O, Schett G, Sandner P, Distler JH.
    Ann Rheum Dis; 2015 Aug; 74(8):1621-5. PubMed ID: 25817717
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 47.